{
    "id": "row_000045",
    "result": {
        "title": "The Essence of Machine and Deep Learning in Antidepressant Pharmacogenomics",
        "introduction": "Machine learning and deep learning techniques are increasingly recognized as a crucial basis for pharmacogenomics research concerning antidepressant treatments in patients with major depressive disorder (MDD).",
        "main_body": "The essence of applying various machine and deep learning approaches to pharmacogenomics research for antidepressant treatment prediction is that these techniques serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD). They are leveraged to determine treatment prediction and identify potential biomarkers for antidepressant treatments in MDD. This research often integrates these approaches with neuroimaging and multi-omics data to achieve its objectives.",
        "conclusion": "In summary, machine and deep learning provide a powerful framework for advancing pharmacogenomics research, enabling more precise predictions of antidepressant treatment efficacy and the discovery of associated biomarkers, ultimately aiming to personalize treatment for MDD patients."
    },
    "prompt": "You will be given a JSON object as a string which contains a series of related search queries and their retrieved documents ('hits'). Do not make answer from external knowledge. You must make answer inside of Context.\nYour main task is to answer the specific 'Question' provided below. Use the entire JSON data as context to formulate your answer, paying close attention to the 'text' fields within the 'hits' lists.\n\nThe JSON data has a list of queries. The 'original' query is the one you need to answer. The other queries are supplementary and provide additional context.\nDo not use \"*\", \"-\" symbols. Please don't use \"**\" to emphasize words. Don't answer in markdown format just write it simple.\n\nIf the 'Question' is in Korean, format your answer in Korean as follows:\n##제목##\n\n##서론##\n\n##본론##\n\n##결론##\n\nIf the 'Question' is in English, format your answer in English as follows, If English then Just write title inside of ##{Title}##:\n##{Title}##\n\n##Introduction##\n\n##Main Body##\n\n##Conclusion##\n\n--- Context ---\n{\n  \"id\": \"row_000045\",\n  \"model_name\": \"Alibaba-NLP/gte-multilingual-base\",\n  \"timestamp_kst\": \"2025-09-08T23:55:38.486426+09:00\",\n  \"trial_id\": \"cb56c51c\",\n  \"queries\": [\n    {\n      \"query\": \"What is the essence of applying various machine and deep learning approaches to pharmacogenomics research for antidepressant treatment prediction?\",\n      \"query_meta\": {\n        \"type\": \"original\"\n      },\n      \"top_k\": 50,\n      \"hits\": [\n        {\n          \"rank\": 1,\n          \"score\": 0.8611539602279663,\n          \"doc_id\": \"ART002777203\",\n          \"title\": \"Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments\",\n          \"abstract\": \"A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.\",\n          \"source\": \"http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=ART002777203&target=NART&cn=ART002777203\",\n          \"author\": \"nan\",\n          \"embedding_mode\": \"3*title+abstract\",\n          \"embedding_text\": \"Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.\"\n        }\n      ]\n    },\n    {\n      \"query\": \"What are the primary challenges in predicting antidepressant treatment response using pharmacogenomic data?\",\n      \"query_meta\": {\n        \"type\": \"single_hop\",\n        \"index\": 0\n      },\n      \"top_k\": 50,\n      \"hits\": [\n        {\n          \"rank\": 1,\n          \"score\": 0.7721887230873108,\n          \"doc_id\": \"ART002777203\",\n          \"title\": \"Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments\",\n          \"abstract\": \"A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.\",\n          \"source\": \"http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=ART002777203&target=NART&cn=ART002777203\",\n          \"author\": \"nan\",\n          \"embedding_mode\": \"3*title+abstract\",\n          \"embedding_text\": \"Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.\"\n        }\n      ]\n    },\n    {\n      \"query\": \"How do machine learning and deep learning approaches help overcome these challenges in pharmacogenomics research for antidepressant treatment prediction?\",\n      \"query_meta\": {\n        \"type\": \"single_hop\",\n        \"index\": 1\n      },\n      \"top_k\": 50,\n      \"hits\": [\n        {\n          \"rank\": 1,\n          \"score\": 0.8618699908256531,\n          \"doc_id\": \"ART002777203\",\n          \"title\": \"Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments\",\n          \"abstract\": \"A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.\",\n          \"source\": \"http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=ART002777203&target=NART&cn=ART002777203\",\n          \"author\": \"nan\",\n          \"embedding_mode\": \"3*title+abstract\",\n          \"embedding_text\": \"Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.\"\n        }\n      ]\n    }\n  ],\n  \"meta\": {\n    \"model\": \"gemini-2.5-flash\",\n    \"temperature\": 0.2\n  }\n}\n\n--- Question ---\nWhat is the essence of applying various machine and deep learning approaches to pharmacogenomics research for antidepressant treatment prediction?\n\n",
    "model": "models/gemini-2.5-flash",
    "retrival": {
        "id": "row_000045",
        "model_name": "Alibaba-NLP/gte-multilingual-base",
        "timestamp_kst": "2025-09-08T23:55:38.486426+09:00",
        "trial_id": "cb56c51c",
        "queries": [
            {
                "query": "What is the essence of applying various machine and deep learning approaches to pharmacogenomics research for antidepressant treatment prediction?",
                "query_meta": {
                    "type": "original"
                },
                "top_k": 50,
                "hits": [
                    {
                        "rank": 1,
                        "score": 0.8611539602279663,
                        "doc_id": "ART002777203",
                        "title": "Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments",
                        "abstract": "A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.",
                        "source": "http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=ART002777203&target=NART&cn=ART002777203",
                        "author": "nan",
                        "embedding_mode": "3*title+abstract",
                        "embedding_text": "Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms."
                    }
                ]
            },
            {
                "query": "What are the primary challenges in predicting antidepressant treatment response using pharmacogenomic data?",
                "query_meta": {
                    "type": "single_hop",
                    "index": 0
                },
                "top_k": 50,
                "hits": [
                    {
                        "rank": 1,
                        "score": 0.7721887230873108,
                        "doc_id": "ART002777203",
                        "title": "Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments",
                        "abstract": "A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.",
                        "source": "http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=ART002777203&target=NART&cn=ART002777203",
                        "author": "nan",
                        "embedding_mode": "3*title+abstract",
                        "embedding_text": "Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms."
                    }
                ]
            },
            {
                "query": "How do machine learning and deep learning approaches help overcome these challenges in pharmacogenomics research for antidepressant treatment prediction?",
                "query_meta": {
                    "type": "single_hop",
                    "index": 1
                },
                "top_k": 50,
                "hits": [
                    {
                        "rank": 1,
                        "score": 0.8618699908256531,
                        "doc_id": "ART002777203",
                        "title": "Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments",
                        "abstract": "A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.",
                        "source": "http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=ART002777203&target=NART&cn=ART002777203",
                        "author": "nan",
                        "embedding_mode": "3*title+abstract",
                        "embedding_text": "Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms."
                    }
                ]
            }
        ],
        "meta": {
            "model": "gemini-2.5-flash",
            "temperature": 0.2
        }
    }
}